Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections

Abstract Background Evaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic hepatits B(CHB) with HBeAg-negative. Methods This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who re...

Full description

Bibliographic Details
Main Authors: Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Infectious Diseases
Subjects:
Chronic hepatitis B
eGFR
HBeAg
Telbivudine
Online Access:https://doi.org/10.1186/s12879-020-05642-y

Internet

https://doi.org/10.1186/s12879-020-05642-y

Similar Items